Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review

Zhe Zhang(First Hospital of China Medical University), Mingfang Zhao(First Hospital of China Medical University), Jiayun Zou(First Hospital of China Medical University), Mingxia Ma(First Hospital of China Medical University), Rui Ding(Zhejiang University), Xiujuan Qu(First Hospital of China Medical University), Yishan Chen(Jiangxi University of Science and Technology), Yunpeng Liu(Shenyang Institute of Automation), Lixin Han(First Hospital of China Medical University), Junli Hao(First Hospital of China Medical University), Lina Zhang(Xi'an University of Science and Technology)
Oncotarget
July 7, 2017
10.18632/oncotarget.19089
Cited by 14

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417